Cargando…

Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181)

Budigalimab is a humanized, recombinant, Fc mutated IgG1 monoclonal antibody targeting programmed cell death 1 (PD‐1) receptor, currently in phase I clinical trials. The safety, efficacy, pharmacokinetics (PKs), pharmacodynamics (PDs), and budigalimab dose selection from monotherapy dose escalation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Powderly, John, Spira, Alexander, Kondo, Shunsuke, Doi, Toshihiko, Luke, Jason J., Rasco, Drew, Gao, Bo, Tanner, Minna, Cassier, Philippe A., Gazzah, Anas, Italiano, Antoine, Tosi, Diego, Afar, Daniel E., Parikh, Apurvasena, Engelhardt, Benjamin, Englert, Stefan, Lambert, Stacie L., Kasichayanula, Sreeneeranj, Mensing, Sven, Menon, Rajeev, Vosganian, Gregory, Tolcher, Anthony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877859/ https://www.ncbi.nlm.nih.gov/pubmed/32770720 http://dx.doi.org/10.1111/cts.12855

Ejemplares similares

First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma
por: Italiano, Antoine, et al.
Publicado: (2021)

Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab
por: Lambert, Stacie L., et al.
Publicado: (2022)

CFTR Rescue in Intestinal Organoids with GLPG/ABBV-2737, ABBV/GLPG-2222 and ABBV/GLPG-2451 Triple Therapy
por: de Poel, Eyleen, et al.
Publicado: (2021)

Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors
por: Luke, Jason J, et al.
Publicado: (2021)

A Population Pharmacokinetic Meta‐Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients
por: Stodtmann, Sven, et al.
Publicado: (2021)

Bedside to Bench: Integrating Quantitative Clinical Pharmacology and Reverse Translation to Optimize Drug Development
por: Gibbs, John P., et al.
Publicado: (2017)

Evolution of preclinical characterization and insights into clinical pharmacology of checkpoint inhibitors approved for cancer immunotherapy
por: Kasichayanula, Sreeneeranj, et al.
Publicado: (2022)

Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study
por: LoRusso, Patricia, et al.
Publicado: (2022)

In vivo kinetics of Wolbachia depletion by ABBV-4083 in L. sigmodontis adult worms and microfilariae
por: Hübner, Marc P., et al.
Publicado: (2019)

Transcriptome Analysis of Duck and Chicken Brains Infected with Aquatic Bird Bornavirus-1 (ABBV-1)
por: Pham, Phuc H., et al.
Publicado: (2022)

The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
por: Baumgartner, Christina K., et al.
Publicado: (2023)

Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
por: Kasichayanula, Sreeneeranj, et al.
Publicado: (2018)

Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients
por: Yuda, Junichiro, et al.
Publicado: (2023)

Discovery of ABBV-4083, a novel analog of Tylosin A that has potent anti-Wolbachia and anti-filarial activity
por: von Geldern, Thomas W., et al.
Publicado: (2019)

Identification of GLPG/ABBV-2737, a Novel Class of Corrector, Which Exerts Functional Synergy With Other CFTR Modulators
por: de Wilde, Gert, et al.
Publicado: (2019)

ABBV-744 as a potential inhibitor of SARS-CoV-2 main protease enzyme against COVID-19
por: Fakhar, Zeynab, et al.
Publicado: (2021)

PB2088: ABBV-383 IN COMBINATION WITH ANTI-CANCER REGIMENS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DOSE ESCALATION AND EXPANSION
por: Valdes, Cesar Rodriguez, et al.
Publicado: (2023)

PB2224: ABBV-744 ALONE OR IN COMBINATION WITH RUXOLITINIB OR NAVITOCLAX IN PATIENTS WITH MYELOFIBROSIS: A PHASE 1B STUDY
por: Mascarenhas, John, et al.
Publicado: (2023)

ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition
por: Anderson, Mark G., et al.
Publicado: (2021)

Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety
por: Lee, Edward, et al.
Publicado: (2019)

ABBV-011, A Novel, Calicheamicin-Based Antibody–Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors
por: Wiedemeyer, Wolf R., et al.
Publicado: (2022)

Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program
por: Blay, Jean-Yves, et al.
Publicado: (2013)

A phase 1 study of the pan‐bromodomain and extraterminal inhibitor mivebresib (ABBV‐075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia
por: Borthakur, Gautam, et al.
Publicado: (2021)

Crowdsourced Asparagus Urinary Odor Population Kinetics
por: Ramamoorthy, Anuradha, et al.
Publicado: (2017)

Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS‐CoV‐2 neutralizing monoclonal antibody ABBV‐47D11 in patients with COVID‐19
por: Shebley, Mohamad, et al.
Publicado: (2022)

ABBV-744 induces autophagy in gastric cancer cells by regulating PI3K/AKT/mTOR/p70S6k and MAPK signaling pathways
por: Wang, Kun, et al.
Publicado: (2023)

Targetry for a &#181,<sup>+</sup> &#181,<sup>-</sup> Collider
por: Kirk, H G
Publicado: (1999)

P862: A PHASE 1 FIRST-IN-HUMAN MONOTHERAPY STUDY OF ABBV-383, A BCMA × CD3 BISPECIFIC T-CELL–REDIRECTING ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Weisel, Katja, et al.
Publicado: (2023)

Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2013)

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
por: D'Souza, Anita, et al.
Publicado: (2022)

Lucio Rossi in building 181
por: Struik, Michael
Publicado: (2018)

Hydraulic press in Hall 181.
por: Jean-Luc Caron
Publicado: (1997)

Hydraulic press in Hall 181.
por: Jean-Luc Caron
Publicado: (1997)

Hydraulic press in Hall 181.
por: Jean-Luc Caron
Publicado: (1997)

Hydraulic press in Hall 181.
por: Jean-Luc Caron
Publicado: (1997)

Hydraulic press in Hall 181.
por: Jean-Luc Caron
Publicado: (1997)

Hydraulic press in Hall 181.
por: Jean-Luc Caron
Publicado: (1997)

Hydraulic press in Hall 181.
por: Jean-Luc Caron
Publicado: (1997)

Magnet installaion in building 181
por: Sylvie Prodon
Publicado: (2006)

Shoulder girdle resection: surgical technique modification and introduction of a new classification system
por: Shehadeh, Ahmad, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vc6gr0qdo0fm4geb1h8tfno3oi